Pfizer, BioNTech Fail to Ax Alnylam Patents, For Now (Correct)

A federal judge denied Pfizer Inc. and BioNTech SE’s first attempt to knock out Alnylam Pharmaceuticals Inc.’s patents in a case over the partners’ Covid-19 vaccines. Three requests based on other theories remain undecided.

Judge Colm F. Connolly, in an order issued April 29 in the US District Court for the District of Delaware, rejected arguments that Alnylam’s patents are invalid because of improper claim structure and inadequate written description. He denied the motion without deciding the underlying validity questions

Alnylam is seeking damages for Comirnaty’s alleged infringement of five patents related to lipid nanoparticle technology, which uses tiny balls ...